Another clinical trial to see efficacy of dual EGFR blockade in the presence of erlotinib and panitumumab with or without chemotherapy for advanced CRC is currently being performed with patients harboring wild-type KRAS gene (NCT00940316). The gene discussed is KRAS; the disease is colorectal carcinoma.